Related Experiment Video
Updated: Jan 20, 2026
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Efficacy of pentoxifylline treatment for neonatal sepsis: a meta-analysis of randomized controlled studies
Jun Tian1, Peifang Shen1, Kaiyu Pan1
1Department of pediatrics, The First people's Hospital of Xiaosha, Hangzhou, China.
Insights
Pentoxifylline treatment shows promise for neonatal sepsis, significantly reducing hospital stays and metabolic acidosis. Further analysis suggests a potential decrease in mortality for this vulnerable population.
Area of Science:
- Neonatal Medicine
- Pharmacology
- Critical Care Medicine
Background:
- Neonatal sepsis is a significant cause of mortality and morbidity in newborns.
- Pentoxifylline, a phosphodiesterase inhibitor, has immunomodulatory effects that may benefit sepsis patients.
- The efficacy of pentoxifylline in treating neonatal sepsis requires robust evaluation.
Purpose of the Study:
- To systematically review and meta-analyze randomized controlled trials (RCTs) on pentoxifylline for neonatal sepsis.
- To evaluate the impact of pentoxifylline on key clinical outcomes, including mortality, hospital stay, and specific sepsis-related complications.
- To assess the safety and efficacy of pentoxifylline in this patient population.
Main Methods:
- A comprehensive search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was conducted.
- Seven RCTs involving 439 neonates with sepsis were included in the meta-analysis.
- Data extraction and quality assessment were performed independently by two investigators, with analysis using a random-effect model.
Main Results:
- Pentoxifylline treatment was associated with a significant reduction in hospital stay (Std. MD = -0.61; P = 0.0002) and metabolic acidosis (RR = 0.38; P = 0.0006).
- No significant impact was observed on mortality (RR = 0.59; P = 0.13) or inflammatory markers (TNF-α, CRP, IL-6) in the initial analysis.
- Sensitivity analysis, excluding one study, revealed a significant reduction in mortality (RR = 0.50; P = 0.02).
Conclusions:
- Pentoxifylline treatment may be a beneficial adjunctive therapy for neonatal sepsis.
- The drug is associated with reduced hospital stay and metabolic acidosis.
- Further research, particularly large-scale trials, is warranted to confirm its efficacy in reducing mortality.
Introduction:
Pentoxifylline may be an important approach to treat neonatal sepsis. However, its use has not been well established. We conduct a systematic review and meta-analysis to evaluate the efficacy of pentoxifylline treatment for neonatal sepsis.
Methods:
PubMed, Embase, and the Cochrane Central Register of Controlled Trials are searched. Randomized controlled trials (RCTs) assessing the influence of pentoxifylline treatment on neonatal sepsis are included. Two investigators independently have searched articles, extracted data, and assessed the quality of included studies. This meta-analysis is performed using the random-effect model.
Results:
Seven RCTs involving 439 patients are included in the meta-analysis. Compared with control intervention for neonatal sepsis, pentoxifylline treatment is associated with reduced hospital stay (Std. MD = -0.61; 95% CI = -0.93 to - 0.29; P = 0.0002) and metabolic acidosis (RR = 0.38; 95% CI = 0.22 to 0.66; P = 0.0006), but has no remarkable impact on mortality (RR = 0.59; 95% CI = 0.30 to 1.16; P = 0.13), serum TNF-α (Std. MD = -0.38; 95% CI = -1.29 to 0.52; P = 0.41), serum CRP (Std. MD = -0.25; 95% CI = -0.92 to 0.42; P = 0.47), plasma IL-6 (Std. MD = -0.13; 95% CI = -0.41 to 0.15; P = 0.37), disseminated intravascular coagulopathy (RR = 0.55; 95% CI = 0.25 to 1.21; P = 0.14), and oliguria/anuria (RR = 0.77; 95% CI = 0.28 to 2.16; P = 0.62). In addition, pentoxifylline treatment can significantly reduce mortality (RR = 0.50; 95% CI = 0.29 to 0.88; P = 0.02) after excluding the study conducted by Akdag during the sensivity analysis.
Conclusions:
Pentoxifylline treatment may be associated with reduced mortality and hospital stay in neonatal sepsis.
Related Concept Videos
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:29Self-Efficacy
01:04Random Error
01:09Random Variables
Uppercase letters such as X or Y denote a random variable. Lowercase letters like x or y denote the value of a random variable. If X is a random variable, then X is written in words, and x is given as a number.
For example, let X = the...
01:13Randomized Experiments
Simple randomization
Simple...